Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Science ; 382(6668): eadf6249, 2023 10 20.
Article in English | MEDLINE | ID: mdl-37856615

ABSTRACT

Targeted protein degradation can provide advantages over inhibition approaches in the development of therapeutic strategies. Lysosome-targeting chimeras (LYTACs) harness receptors, such as the cation-independent mannose 6-phosphate receptor (CI-M6PR), to direct extracellular proteins to lysosomes. In this work, we used a genome-wide CRISPR knockout approach to identify modulators of LYTAC-mediated membrane protein degradation in human cells. We found that disrupting retromer genes improved target degradation by reducing LYTAC recycling to the plasma membrane. Neddylated cullin-3 facilitated LYTAC-complex lysosomal maturation and was a predictive marker for LYTAC efficacy. A substantial fraction of cell surface CI-M6PR remains occupied by endogenous M6P-modified glycoproteins. Thus, inhibition of M6P biosynthesis increased the internalization of LYTAC-target complexes. Our findings inform design strategies for next-generation LYTACs and elucidate aspects of cell surface receptor occupancy and trafficking.


Subject(s)
Lysosomes , Membrane Proteins , Proteolysis Targeting Chimera , Proteolysis , Receptor, IGF Type 2 , Humans , HeLa Cells , Lysosomes/metabolism , Membrane Proteins/metabolism , Receptor, IGF Type 2/genetics , Receptor, IGF Type 2/metabolism , Cullin Proteins/metabolism , Proteolysis Targeting Chimera/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...